StELLAR: Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery
Study Details
Study Description
Brief Summary
To assess the safety and preliminary efficacy of combining intravenous rt-PA with transcranial laser therapy (TLT) with the NeuroThera® Laser System (referred to hereafter as NTS) in subjects treated for acute ischemic stroke. Treatment with IV rt-PA must begin within 3 hours of symptom onset, and the initiation of TLT procedure must be feasible for each subject within 6 hours of stroke onset. The NeuroThera® Laser System is an investigational device that provides noninvasive transcranial laser therapy to subjects diagnosed with acute ischemic stroke. The wavelength of the laser light is in the infrared zone of the electromagnetic spectrum and is invisible to the naked eye.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This study is a phase II (n= 200), prospective, double-blind, randomized, sham-controlled, multicenter, safety study of intravenous (IV) rt-PA alone versus IV rt-PA plus TLT (Transcranial Laser Therapy) at approximately 10 investigational sites (United States only). The primary endpoint for this safety study is occurrence of symptomatic intracranial hemorrhages at 36 - 48 hours after stroke symptom onset.
Symptomatic hemorrhage will be defined as deterioration of more than 4 points on the NIHSS lasting at least 72 hours accompanied by intracranial hemorrhage in the distribution of the neurological deficit as identified by neuroimaging scans. All follow up neuroimaging scans will be reviewed centrally by an independent reviewer for the presence or absence of hemorrhage on the 36-48 hour scan.
The secondary endpoints for this study are as follows:
-
Hemorrhagic transformation without clinical consequences (asymptomatic) within 36-48 hours. All follow-up neuroimaging scans will be reviewed centrally by an independent reviewer for the presence or absence of hemorrhage on the 36-48 hour scan.
-
Mortality
-
The modified Rankin Scale (mRS) score dichotomized as 0-1 versus an mRS score of 2-6 at 90 days or the last rating in patients that develop intracerebral hemorrhages
-
Frequency of SAEs and AEs This study is a phase II (N = 200), prospective, double-blind, randomized, sham controlled, multicenter, safety study of intravenous (IV) tissue plasminogen activator (rt-PA) versus IV rt-PA plus transcranial laser therapy (TLT) at approximately 10 investigational sites.
The study population will be randomized into two arms. One group will receive a sham TLT procedure (Sham Control Group or SCG) and the second group will receive an active TLT procedure (TLTG).
The randomization ratio of SCG and TLTG will be 1:1 and will be stratified in order to ensure balanced subject distribution between the treatment and sham-controlled groups for the following factors:
-
Stroke severity as measured by National Institute of Health Stroke Scale (NIHSS) at baseline (stratified as 7-9, 10-13, 14-17)
-
Study Site There are 6 visits in the study. The purpose of the Visit 1 will be to determine and confirm the eligibility of patients for participation in the StELLAR Study and document baseline information about the subject and their stroke event. This will include all of the following standard of care tests and procedures: a non contrast head CT scan performed prior to rt-PA administration, vital signs, height , weight ,physical exam, finger stick or blood glucose, serum or urine pregnancy test (if women of childbearing potential). In addition, the following data will be obtained: prestroke mRS, NIHSS, presumed location of stroke and vascular territory, start and stop date and time of the IV rt-PA treatment and dose given, date and time of stroke onset, date and time of arrival to the hospital, demographic data (date of birth, gender, ethnicity),sociodemographic data (education, marital status, social support prior to stroke),medical and surgical history (specific cardiovascular, neurological, endocrine, and other standard questions asked), method of contraception use (for women of child bearing potential), prior (three days prior to Screening) and current concomitant medication use, smoking history, adverse events from the time of obtaining informed consent. To be eligible for the study, the administration of rt-PA should follow the guidelines outlined by the National Institutes of Neurologic Disorders. Patients meeting the inclusion/exclusion criteria will be enrolled into the study after written informed consent is obtained by the patient or their legally authorized representative.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Sham Comparator: IV tPA + Sham Transcranial Laser Therapy Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. |
Device: Transcranial Laser Therapy
Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
Other Names:
|
| Active Comparator: IV tPA +Transcranial Laser Therapy Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. |
Device: Transcranial Laser Therapy
Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Symptomatic Intracranial Hemorrhages [36 hours from tPA initiation]
- Percentage of Participants With Modified Rankin Scale (0 - 1) [90 Days from Stroke Onset]
Measures the degree of disability or dependence in the daily activities. Minimum score = 0 (best outcome - No symptoms); Maximum Score = 6 (worse outcome - dead)
Eligibility Criteria
Criteria
Inclusion Criteria:
Subjects may be included in the study only if they meet all of the following criteria:
-
Subject is at least 40 years of age at screening, but has not had their 81st birthday.
-
Subject has received IV rt-PA per the NINDS rt-PA Protocol Guidelines within 3 hours of symptom onset for an acute ischemic stroke.
-
Subject is diagnosed with acute ischemic stroke and presents to the health care facility at a time such that initiation of NTS procedure is feasible within 6 hours of the time of stroke onset. The time of stroke onset is defined as the time at which a change in the baseline neurological function occurred. If the time is not known (e.g., the subject awakens from sleep with new symptoms), the last time the patient was observed to be neurologically intact must be considered to be the time of onset.
-
Documented baseline NIHSS score of > 7 and < 17 prior to IV rt-PA administration. Subjects who transfer from other facilities after receiving IV rt-PA must have a documented NIHSS by a certified examiner prior to initiation of rt-PA treatment. Documentation of NIHSS score via telemedicine is acceptable if performed by a certified examiner. Subjects who improve prior to NTS procedure will still be treated, unless their NIHSS improves to 0.
-
Full functional independence just prior to the present stroke episode as defined by the following criteria:
-
Estimated prestroke mRS score 0 or 1.
-
Ambulates independently, may need a cane or walker, but does not need the assistance of another person.
-
Absence of a medical/physical/mental condition that substantially limits the subject's ability to work, study, participate in leisure activities, or look after family at home
-
Completely independent, does not need supervision (may live with other individuals, but could live alone if necessary)
-
Negative serum or urine pregnancy test in females of childbearing potential.
-
Subject (or legally authorized representative) provides written Informed Consent in compliance with local regulations prior to enrollment into this study.
-
The subject (and caregiver, if applicable) is willing to participate in this study for at least 90 days after the onset of stroke.-
Exclusion Criteria:
-
Evidence on from a pre-tPA head CT of an intracranial, subdural, or subarachnoid hemorrhage or clinical presentation suggestive of subarachnoid hemorrhage even if the initial neuroimaging scan is normal.
-
Clinical presentation consistent with a brainstem or cerebellar stroke
-
A rapidly improving neurological status that in the opinion of the investigator will make the subject unsuitable for participation in this study or patient rapidly improves to NIHSS of 0 by start of NTS procedure.
-
The subject had a seizure at stroke onset or within the 7 days prior to stroke onset.
-
Sustained blood glucose > 300 mg/dl or < 60 mg/dl
-
Subjects who, on repeated measurement, have a systolic blood pressure > 185, or a diastolic blood pressure > 110mmHg, post rt-PA administration, or it is the opinion of the investigator that aggressive treatment to reduce blood pressure post thrombolysis is required to keep pressure within these limits.
-
Presumed and/or confirmed septic embolus.
-
The subject has a history of CNS vascular wall disease (e.g. aneurysm, AVM).
-
The subject has a history of CNS disease or damage (e.g. neoplasm or dementia) which may influence the subject's outcome assessment.
-
The subject has a significant skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on their scalp that is found to be directly below three or more TLT procedure sites.
-
Planned or actual use of any intra-arterial thrombolytic medication or a clot retrieval device, or any diagnostic or therapeutic interventional neurovascular procedure, including mechanical recanalization, whether successful or unsuccessful, during this stroke episode.
-
Subject previously participated in another investigational drug or device trial within the preceding four weeks.
-
Subject is a female who is pregnant or lactating (within the previous 30 days),or who is of child-bearing potential unless she is surgically sterile or she and/or her partner are using a medically acceptable method of birth control.
-
The subject has an implant of any kind in the head (i.e. clipped aneurysm, embolised AVM, implantable shunt - Hakim valve).
-
Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment.
-
The subject participated in the NEST-1, NEST-2, or NEST-3 Study.
-
The subject has any co-existing or terminal disease that may limit life expectancy or any medical condition (e.g. morbid obesity, substance abuse) that may, in the clinical judgment of the Investigator, independently influence the subject's outcome during the course of the study.
-
The subject is otherwise determined, based on the opinion of the Investigator,to be an unsuitable candidate for enrollment in this study. -
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Swedish Medical Center | Englewood | Colorado | United States | 80113 |
| 2 | Palmetto Health Richland | Columbia | South Carolina | United States | 29203 |
| 3 | Providence Medical Research Center | Spokane | Washington | United States | 99204 |
Sponsors and Collaborators
- University of California, San Diego
- National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
- Principal Investigator: Thomas Hemmen, MD, PhD, University of California, San Diego
Study Documents (Full-Text)
None provided.More Information
Publications
- Hacke W, Schellinger PD, Albers GW, Bornstein NM, Dahlof BL, Fulton R, Kasner SE, Shuaib A, Richieri SP, Dilly SG, Zivin J, Lees KR; NEST 3 Committees and Investigators. Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial. Stroke. 2014 Nov;45(11):3187-93. doi: 10.1161/STROKEAHA.114.005795. Epub 2014 Oct 7.
- Huisa BN, Stemer AB, Walker MG, Rapp K, Meyer BC, Zivin JA; NEST-1 and -2 investigators. Transcranial laser therapy for acute ischemic stroke: a pooled analysis of NEST-1 and NEST-2. Int J Stroke. 2013 Jul;8(5):315-20. doi: 10.1111/j.1747-4949.2011.00754.x. Epub 2012 Feb 2.
- Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, Fisher M, Hacke W, Holt W, Ilic S, Kasner S, Lew R, Nash M, Perez J, Rymer M, Schellinger P, Schneider D, Schwab S, Veltkamp R, Walker M, Streeter J; NeuroThera Effectiveness and Safety Trial-2 Investigators. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009 Apr;40(4):1359-64. doi: 10.1161/STROKEAHA.109.547547. Epub 2009 Feb 20.
- StELLAR
- P50NS044148
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Sham Transcranial Laser Therapy | Transcranial Laser Therapy |
|---|---|---|
| Arm/Group Description | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. |
| Period Title: Overall Study | ||
| STARTED | 7 | 5 |
| COMPLETED | 7 | 5 |
| NOT COMPLETED | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Sham Transcranial Laser Therapy | Transcranial Laser Therapy | Total |
|---|---|---|---|
| Arm/Group Description | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. | Total of all reporting groups |
| Overall Participants | 7 | 5 | 12 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
64.1
(8.5)
|
66.8
(12.7)
|
65.2
(10.0)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
3
42.9%
|
2
40%
|
5
41.7%
|
| Male |
4
57.1%
|
3
60%
|
7
58.3%
|
| Randomization NIH Stroke Scale (score on a scale) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [score on a scale] |
12.3
(3.2)
|
15.0
(2.4)
|
13.4
(3.1)
|
| Post-tPA Baseline/Treatment NIH Stroke Scale (score on a scale) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [score on a scale] |
8.7
(5.4)
|
9.6
(5.4)
|
9.1
(5.2)
|
Outcome Measures
| Title | Symptomatic Intracranial Hemorrhages |
|---|---|
| Description | |
| Time Frame | 36 hours from tPA initiation |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Sham Transcranial Laser Therapy | Transcranial Laser Therapy |
|---|---|---|
| Arm/Group Description | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. |
| Measure Participants | 7 | 5 |
| Number [participants] |
0
0%
|
0
0%
|
| Title | Percentage of Participants With Modified Rankin Scale (0 - 1) |
|---|---|
| Description | Measures the degree of disability or dependence in the daily activities. Minimum score = 0 (best outcome - No symptoms); Maximum Score = 6 (worse outcome - dead) |
| Time Frame | 90 Days from Stroke Onset |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Sham Transcranial Laser Therapy | Transcranial Laser Therapy |
|---|---|---|
| Arm/Group Description | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. |
| Measure Participants | 7 | 5 |
| Number [percentage of participants] |
42.9
612.9%
|
40.0
800%
|
Adverse Events
| Time Frame | ||||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Sham Transcranial Laser Therapy | Transcranial Laser Therapy | ||
| Arm/Group Description | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. | Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset. Transcranial Laser Therapy: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site. | ||
All Cause Mortality |
||||
| Sham Transcranial Laser Therapy | Transcranial Laser Therapy | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Sham Transcranial Laser Therapy | Transcranial Laser Therapy | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/7 (42.9%) | 2/5 (40%) | ||
| Cardiac disorders | ||||
| Cardiac failure congestive | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Gastrointestinal disorders | ||||
| Clostridium colitis | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Infections and infestations | ||||
| Sepsis | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Nervous system disorders | ||||
| Neurological symptom | 1/7 (14.3%) | 1 | 1/5 (20%) | 1 |
| Renal and urinary disorders | ||||
| Renal failure acute | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Vascular disorders | ||||
| Hypotension | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
Other (Not Including Serious) Adverse Events |
||||
| Sham Transcranial Laser Therapy | Transcranial Laser Therapy | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 6/7 (85.7%) | 5/5 (100%) | ||
| Blood and lymphatic system disorders | ||||
| Anaemia | 0/7 (0%) | 0 | 2/5 (40%) | 2 |
| Cardiac disorders | ||||
| Atrial fibrillation | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Endocrine disorders | ||||
| Diabetes mellitus | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Hypothyroidism | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Eye disorders | ||||
| Dry eye | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Gastrointestinal disorders | ||||
| Consitpation | 0/7 (0%) | 0 | 2/5 (40%) | 2 |
| Diarrhoea | 1/7 (14.3%) | 1 | 1/5 (20%) | 1 |
| Dysphagia | 1/7 (14.3%) | 1 | 2/5 (40%) | 2 |
| Nausea | 1/7 (14.3%) | 1 | 1/5 (20%) | 1 |
| Toothache | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Vomiting | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| General disorders | ||||
| Pyrexia | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Infections and infestations | ||||
| Oral candidiasis | 1/7 (14.3%) | 1 | 1/5 (20%) | 1 |
| Injury, poisoning and procedural complications | ||||
| Renal Injury | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Investigations | ||||
| Blood potassium decreased | 2/7 (28.6%) | 2 | 0/5 (0%) | 0 |
| Blood sodium increased | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Ubiquinone decreased | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Metabolism and nutrition disorders | ||||
| Dehydration | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Hyperlipidaemia | 0/7 (0%) | 0 | 2/5 (40%) | 2 |
| Hyponatraemia | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Malnutrtion | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Vitamin B complex deficiency | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Vitamin D deficiency | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Neck pain | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Nervous system disorders | ||||
| Carotid artery stenosis | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Dementia | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Drooling | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Headache | 2/7 (28.6%) | 2 | 0/5 (0%) | 0 |
| Insomnia | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Neurogenic bladder | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Psychiatric disorders | ||||
| Agitation | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Depression | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Mental status changes | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Renal and urinary disorders | ||||
| Renal failure | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Urinary Tract Infection | 1/7 (14.3%) | 1 | 2/5 (40%) | 3 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Acute respiratory distress syndrome | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Sleep apnoea syndrome | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Skin and subcutaneous tissue disorders | ||||
| Dry skin | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Rash | 1/7 (14.3%) | 1 | 0/5 (0%) | 0 |
| Skin burning sensation | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
| Vascular disorders | ||||
| Carotid artery stenosis | 0/7 (0%) | 0 | 2/5 (40%) | 2 |
| Deep vein thrombosis | 1/7 (14.3%) | 1 | 1/5 (20%) | 2 |
| Thrombophlebitis superficial | 0/7 (0%) | 0 | 1/5 (20%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Thomas Hemmen |
|---|---|
| Organization | University of California, San Diego |
| Phone | 858-657-7190 |
| themmen@ucsd.edu |
- StELLAR
- P50NS044148